Turning red after consuming alcohol may seem like a mere social inconvenience. Yet, this flushing response is caused by an accumulation of acetaldehyde, a carcinogenic intermediate of alcohol metabolism. Aldehyde dehydrogenase 2 (ALDH2) deficiency, the result of a point mutation, produces a less efficient ALDH2. The resulting accumulation of acetaldehyde greatly increases the risk of developing esophageal and head and neck cancers. In this study, we produced recombinant ALDH2 in the probiotic E. coli
Introduction
ALDH2 Deficiency ALDH2 deficiency, more commonly known as Alcohol Flushing Syndrome or Asian Glow, is a genetic condition that interferes with the metabolism of alcohol. Normally, ethanol is first converted to acetaldehyde (a toxic intermediate) by the enzyme alcohol dehydrogenase (ADH). Then, acetaldehyde is converted to acetate, which can be safely metabolized in the body by aldehyde dehydrogenase 2 (ALDH2) (Figure 1 ). People with ALDH2 deficiency, however, have a point mutation which leads to a less efficient mutant (ALDH2*2), with lower binding affinity to the coenzyme NAD+ [1] , [2] . Enzymatic activity in ALDH2-deficient individuals can be as low as 4% compared to wild type ALDH2*1 activity [2] , [3] , [4] , [5] . As a result, acetaldehyde accumulates and induces an inflammatory response that causes the skin to flush or appear red after drinking alcohol [6] . Facial flushing is the most obvious result of ALDH2 deficiency, but symptoms also include headaches, dizziness, hypotension, and heart palpitations [3] , [7] . ALDH2 deficiency affects 540 million people -8% of the world population. In East Asia (which includes Japan, China, and Korea), this is a much bigger problem, where the number rises to 36% [8] . In our home, Taiwan, approximately 47% of the population carries this genetic mutation -the highest ALDH2-deficient percentage in the world [9] .
Health Concerns & Risks
Turning red after consuming alcohol may seem like a mere social inconvenience. Yet, behind this red complexion lies a far more serious problem. The International Agency for Research on Cancer classifies acetaldehyde associated with alcohol consumption as a Group 1 carcinogen [10] . Alcohol and acetaldehyde have been shown to reduce thymidine incorporation into DNA, interfering with DNA synthesis [11] , [12] . In other studies with human lymphocyte cells, acetaldehyde increased chromosome damage or the frequency of sister-chromatid exchanges [13] , [14] , [15] . When rats were exposed to acetaldehyde, inhalation led to abnormal changes in the nasal mucous membrane, such as degeneration of the tissue, increased cell proliferation, and the development of carcinomas [16] .
Acetaldehyde levels over 50 μM are considered toxic and cause mutations in DNA [17] , [18] . In human studies where roughly 2 to 3 servings of alcohol (0.5-0.6 g alcohol/kg body weight) were ingested, salivary acetaldehyde levels in some individuals reached over 100 μM, compared to normal levels of <20 μM without drinking [19] , [20] , [21] . Figure 2 . Salivary acetaldehyde levels are much higher in heterozygous (ALDH2*1/*2) individuals, compared to homozygous wild type (ALDH2*1/*1) individuals. Salivary and blood acetaldehyde levels were recorded for individuals before and after drinking 0.6 g ethanol/kg body weight. Salivary acetaldehyde levels are also significantly higher than blood acetaldehyde after drinking (figure adapted from Yokoyama et al. , 2008) [20] . Acetaldehyde levels over 50 μM are considered toxic (dashed line).
For people who carry normal, functional ALDH2*1, acetaldehyde can quickly get broken down ( Figure 2 ). For those who are ALDH2-deficient and drink, however, acetaldehyde can accumulate to toxic levels. The strongest effects are seen in the mouth. Studies show that after alcohol consumption, salivary acetaldehyde levels are significantly higher than blood acetaldehyde levels [20] , [22] . Since there are other aldehyde dehydrogenases, such as ALDH1A1, throughout the body to help metabolize acetaldehyde, blood acetaldehyde concentrations remain relatively low [23] . ALDH2 levels are also much higher in the liver, which can break down most acetaldehyde before it enters the bloodstream [24] . This may explain why ALDH2 deficiency does not seem to be directly associated with the development of liver, breast, colorectal, or other common alcohol-related cancers [25] , [9] . Instead, the effects of ALDH2 deficiency are mainly localized in the upper digestive and head and neck region.
Heightened salivary acetaldehyde levels increase the risks of developing esophageal and head and neck cancers. In vivo studies with rats have shown that acetaldehyde administered orally has a tumor-promoting effect (abnormally fast cell growth and division) on the upper respiratory-digestive tract [26] . Depending on how much alcohol is consumed, people with ALDH2 deficiency are two to eight times more likely to develop head and neck cancers (including oral cancer, pharyngeal cancer, laryngeal cancer, etc.), and two to twelve times more likely to develop esophageal cancer compared to people with normal ALDH2*1 [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] .
Today, it is common to simply use cosmetics to conceal the flushing, or take antihistamines to prevent the release of histamines and the resulting redness [36] , [37] , [38] , [39] . These solutions, however, do not actually address the buildup of acetaldehyde, the main contributor to increased esophageal and head and neck cancers risks [40], [41] . On the contrary, these options may actually increase health risks as they conceal the visible symptoms without reducing acetaldehyde levels [8] .
Other treatments include antioxidants that may directly interact with acetaldehyde, but these mainly reduce acetaldehyde accumulation in the blood, instead of treating the acetaldehyde accumulation in saliva [41] , [42] .
To directly address the increased esophageal and head and neck cancer risks, we aim to reduce salivary acetaldehyde levels. Here, we describe testing and delivery of recombinant ALDH2*1 as a candy to maintain normal acetaldehyde levels in the mouths of ALDH2-deficient individuals.
Materials and Methods
Construct Design ALDH2*1 and ALDH2*2 Human ALDH2*1 (iGEM Parts Registry: BBa_M36520; NM_001204889.1) and human ALDH2*2 was modified to remove an internal PstI site and lower the guanine and cytosine content (BBa_K2539150), as recommended by Integrated DNA Technology (IDT). Mutant ALDH2*2 consists of a single G to A point mutation (BBa_K2539250) which leads to a E487K change in the protein. ALDH2 sequences were flanked by an upstream strong promoter and strong ribosome binding site (RBS) combination (BBa_K880005), and a downstream transcription terminator (BBa_B0015) to maximize expression. DNA was synthesized by IDT (BBa_K2539100 and BBa_K2539200), cloned into the standard pSB1C3 Biobrick backbone, and sequenced by Tri-I Biotech.
His-tagged ALDH2*1 and ALDH2*2
For protein purification, an additional N-terminal HIS-tag (6xHIS) was added to the start codon of both ALDH2*1 and ALDH2*2 sequences. DNA was synthesized by IDT (BBa_K2539101 and BBa_K2539201), cloned into the standard pSB1C3 Biobrick backbone, and sequenced by Tri-I Biotech.
Protein Purification
To purify the HIS-tagged proteins, 150 mL of bacterial culture was centrifuged, lysed, and filtered before the cell extract sample was run through a nickel column (GE Healthcare, 11-0033-99). A low-concentration imidazole buffer was run through the column to wash out any non-specific proteins. Finally, we eluted and collected the HIS-tagged ALDH2 proteins by running a high-concentration imidazole buffer through the column (imidazole competes with the HIS tag to bind with nickel ions in the column) [43] . SDS-PAGE was used to check protein content at different steps of the purification process: lysed cell sample, flow-through after the wash buffer, and final eluate containing the purified protein.
Artificial Saliva
To simulate oral conditions, enzymatic activity tests were run using artificial saliva. We chose to prepare artificial saliva using Biotene Dry Mouth OralBalance Gel, a concentrated gel used to treat xerostomia (more commonly known as dry mouth). The gel contains many of the same ingredients as artificial saliva, such as cellulose, glycerin, and xylitol [44] [45] [46] . The mean viscosity of saliva at room temperature is 2.1 centipoise (cP), and the mean viscosity of water at room temperature is 0.95 cP [47] , [48] . We diluted the gel so that the resulting solution would be about 2 times as viscous as water, and then calculated the viscosity of our solutions by adapting the ball drop procedure from Tang (2016) [48] . Diluting 6.5 grams of Biotene gel in 50 mL of water produces a solution with a viscosity of 2.09 cP, which closely mimics saliva.
ALDH2 Enzyme Activity Assay
The reduction of NAD+ to NADH occurs when ALDH2 converts acetaldehyde into acetate. This reaction takes place in a 1:1 ratio, so production of NADH can be used to test ALDH2's ability to metabolize acetaldehyde. We used reagents from a kit (Megazyme, K-ACHYD) and quantified the amount of NADH produced by taking absorbance readings at 340 nm. This wavelength is highly absorbed by the reduced form, NADH, but not the oxidized form, NAD+ [49] , [50] .
We calculated acetaldehyde concentration using the following equation:
, where: Testing Cell Lysate 3 mL bacterial cultures were prepared, and the populations were standardized: the absorbance at OD600 of each culture was measured and cultures were diluted accordingly to achieve the same population in all samples. The cultures were spun down, and the pellets were resuspended and lysed using xTractor Lysis Buffer (Takara Bio, 635671). After lysis, 500 µL of supernatant was transferred into quartz cuvettes containing a pH 9.0 buffer, distilled water, and excess NAD+ (solutions were provided by the Megazyme kit). 50 µL of 0.4 M acetaldehyde was added to initiate the reaction, and absorbance values at 340 nm were recorded for 40 minutes. For all functional tests, the acetaldehyde to water ratio was 1:59 (the total volume was 2.95 mL).
Testing Purified HIS-tagged ALDH2 The procedure described above was followed, except that instead of cell lysates, 5 µg of purified ALDH2 was added into quartz cuvettes containing a pH 9.0 buffer, distilled water or artificial saliva, and excess NAD+.
E. coli Nissle 1917 ( Ec N) Transformation
We obtained a sample of Ec N (Mutaflor) from Pharma-Zentrale GmbH. Bacterial cultures were prepared using LB broth, and the cells were made competent by treatment with calcium chloride. GFP-and ALDH2-expressing plasmids were then chemically transformed into competent Ec N following standard E. coli protocol.
ALDH2 Probiotic Candy Prototype 10 mL of probiotic Ec N culture was pelleted and resuspended in 10 mL distilled water.
To determine the heat threshold of Ec N, the probiotic mixture was heated from 25°C to 80°C, and 3 µL of bacteria was plated at 5°C intervals. To make our own engineered Ec N candy, 30 g of rock sugar and 30 g of gelatin were added to 120 mL of w ater (Figure 3 ). The mixture was heated to about 70°C, or until all of the ingredients fully dissolved. GFP-, ALDH2*1-, and ALDH2*2-Ec N were grown, pelleted, resuspended in 50 µL of water, and added to the gelatin/candy mixture after it cooled down to 55ºC. 3 mL portions were pipetted into ice cube trays and left to solidify and dry over a period of three days. 
Testing EcN Candy
We compared the dissolution rate of our Ec N candy with commercial lozenges (Ricola and Nin Jiom herbal candies) by gently stirring them in artificial saliva at 37°C. We also determined that commercial lozenges dissolve in the mouth after an average of 13 minutes. To test the candy's ability to metabolize acetaldehyde, it was dissolved in artificial saliva at 37°C, centrifuged to isolate ALDH2-Ec N, and then lysed. Cell lysates were tested using artificial saliva at 37°C.
Results & Discussion
Purified ALDH2*1 Metabolizes Acetaldehyde Faster than ALDH2*2 Construct Design, Expression, and Protein Purification HIS-tagged ALDH2*1 and ALDH2*2 expression constructs were assembled (BBa_2539101 and BBa_2539201, respectively, and confirmed by PCR check as well as sequencing (Figure 4 ). SDS-PAGE was used to check protein content at different steps of the purification process: lysed cell sample, flow-through after the wash buffer, and final eluate containing the purified protein (Figure 4 ). HIS-tagged ALDH2*1 should be around 56 kDa. In the initial cell lysate lane, there was a band around 56 kDa (Figure 4 ). This band disappeared in the wash buffer flow-through lane, and reappeared in the eluate. A similar band around 50 kDa was also seen in the eluate when we purified ALDH2*2 (Figure 4 ). For both HIS-tagged samples, there were o ther proteins present in the eluate, but the gels showed that we now have purer samples of both HIS-tagged ALDH2*1 and ALDH2*2 . 
Measuring ALDH2 Enzyme Activity
To test the enzymatic activity of our recombinant ALDH2, we measured the amount of NADH produced when acetaldehyde is converted to acetate ( Figure 5 ). NADH was quantified by taking absorbance readings at 340 nm. This wavelength is highly absorbed by the reduced form, NADH, but not the oxidized form, NAD+ [49] , [50] . Both wild type ALDH2*1 and mutant ALDH2*2 should metabolize acetaldehyde and produce NADH as a result, but ALDH2*1 should be more efficient compared to ALDH2*2. To simulate oral conditions, all tests were run with artificial saliva and at body temperature. Our results show that while both forms of the enzyme can metabolize acetaldehyde, ALDH2*1 produced significantly higher NADH levels (by about 3.5 times) compared to ALDH2*2 ( Figure 5 ). Purified enzyme samples were mixed with acetaldehyde and NAD+ to initiate the reaction. NADH concentration was measured by taking absorbance readings at 340 nm. (C) Enzymatic activity of purified ALDH2*1 and ALDH2*2 was tested in artificial saliva at 37°C. A negative control containing only elution buffer (from the protein purification process) was also included (gray). Under these conditions, ALDH2*1 metabolized significantly more acetaldehyde compared to both ALDH2*2 and the negative control. Error bars represent standard error.
ALDH2 Delivery Using the Probiotic E. coli Nissle 1917 ( Ec N)
In a survey (n = 697) we conducted to gather public opinion, 83% of the people indicated that they prefer treatment in the form of probiotics or oral medication. We tested E c N, a probiotic strain categorized under "generally recognized as safe" (GRAS) by the FDA [51] . It is one of the most frequently used gram-negative oral probiotic strains in research and has been studied for over a century [52] . To test if Ec N can be a chassis for ALDH2*1 delivery, we obtained a sample of Ec N (Mutaflor) from Pharma-Zentrale GmbH and attempted chemical transformation with a GFP expression plasmi d ( Figure 6 ). A lthough transformation efficiency was much lower compared to the common lab strain E. coli K12, we still observed GFP-expressing Ec N colonies, indicating that transformation was successful. Next, we transformed both ALDH2*1 and ALDH2*2-expression constructs (BBa_K2539100 and BBa_K2539200), as well as a GFP positive control into Ec N. The transformations were successful; we observed colonies on all plates and confirmed the plasmids by PCR using the primers VF2 a nd VR (Figure 7) . When we tested the activity of ALDH2*1-Ec N and ALDH2*2-Ec N, we observed a smaller difference in wild type and mutant ALDH2 metabolism. Since these tests were run using cell lysates, there must be other enzymes present in the cells which can also react with NAD+ or NADH; this might explain the closer levels of NADH. However, NADH levels still increased significantly faster for ALDH2*1-Ec N compared to ALDH2*2-Ec N, and did not change for the negative control (inactive ALDH2*1) (Figure 7) . T hese results indicate that Ec N overexpressing ALDH2*1 can successfully metabolize acetaldehyde. (BBa_K2539100 and BBa_K2539200) , and GFP as a positive control. We observed glowing green colonies for the GFP sample, as well as colonies on the ALDH2*1 and ALDH2*2 plates (red arrowhead points to the one bacterial colony of ALDH2*2). (B) PCR check was run using VF2 and VR primers and confirmed the transformations. We observed bands at the expected sizes: BBa_K2539100 and BBa_K2539200 are both 2.1 kb, and the GFP is 1.1 kb. (C) Enzymatic activity was tested using artificial saliva at 37°C. The graph shows relative activity of Ec N lysates containing either ALDH2*1, ALDH2*2, or inactive ALDH2*1 (boiled to denature proteins; negative control). Error bars represent standard error.
Production and Testing of an ALDH2 Probiotics Candy
ALDH2 deficiency mainly increases the risks of developing esophageal and head and neck cancers. To directly target salivary acetaldehyde levels in the region, we envisioned using a candy (similar to a throat lozenge), which remains in the mouth, to steadily deliver recombinant ALDH2*1. The candy will deliver ALDH2*1 either as a purified enzyme or as ALDH2*1-Ec N. Here, we document the production and testing of a probiotic candy.
Production
The candy-making process consists of three stages: dissolving, cooling, and molding [53] . In our temperature threshold tests of GFP-Ec N and ALDH2*1-Ec N, the probiotics remained alive at temperatures lower than 60°C, so we added Ec N to the candy during the cooling stage ( Figure 8 ). The final product carrying GFP-Ec N fluoresced, which shows that we could successfully incorporate living probiotics carrying functional proteins into the candy. 
Testing ALDH2*1-EcN Probiotics Candy
Following the same procedure, we made ALDH2*1-Ec N probiotics candies and tested the candy under simulated oral conditions. As the candy dissolves, it should release ALDH2*1-Ec N. If this occurs too quickly, most of the ALDH2*1-Ec N might be swallowed right away and lose its effect in the mouth. We found that our Ec N candies dissolve at a rate comparable to commercial lozenges (Ricola and Nin Jiom herbal candies) in the lab. Like the lozenges, then, our Ec N candies should also completely dissolve after about 13 minutes in the mouth.
To test our Ec N candy's ability to metabolize acetaldehyde, it was dissolved in artificial saliva, centrifuged to isolate ALDH2*1-Ec N, and then lysed. Enzyme activity assays were performed using cell lysates in artificial saliva at 37°C. We compared three different candies, containing either ALDH2*1-Ec N, ALDH2*2-Ec N, or no Ec N. Our results show that ALDH2*1-Ec N released from the candy is functional and effective at metabolizing acetaldehyde ( Figure 9 ). Figure 9 . Our candy carrying ALDH2*1-Ec N converts acetaldehyde significantly faster than ALDH2*2-EcN. To simulate realistic conditions, the candy was first dissolved in artificial saliva at 37°C before Ec N cell extracts were tested. A candy that did not contain any bacteria served as the negative control. Error bars represent standard error.
Mathematical Modeling: Supplementing ALDH2-deficient Individuals with Recombinant ALDH2*1 to Match Wild Type Enzyme Activity
For ALDH2-deficient individuals, we used mathematical modeling to calculate the amount of ALDH2*1 to consume in order to reduce salivary acetaldehyde to wild type levels. To simulate acetaldehyde concentration in the mouth over time, we first modeled the natural metabolism of alcohol as a two-step reaction ( Figure 10 ). We considered four factors to determine acetaldehyde concentrations in the mouth: initial salivary ethanol and acetaldehyde concentrations, ADH activity, and ALDH2*1 activity. We obtained literature values for salivary ethanol and acetaldehyde concentrations ( Table 1 ) [21] , as well as the reaction rate of ADH. ADH1B*2, a highly prevalent allele among East Asians (found in over 80% of Chinese, Taiwanese, Korean, and Japanese studied populations), converts ethanol to acetaldehyde at a maximum rate of 0.82 µM/sec [54] , [55] . Fina lly, from our own experiments, we determined that at 37°C, 0.222 nM of purified ALDH2*1 enzyme converts acetaldehyde to acetate at a rate of 4.50 nM/sec (data from Figure 5 ). Table 1 . Ethanol and acetaldehyde concentrations in different alcoholic beverages and saliva. Salivary acetaldehyde concentrations were recorded after consuming one mouthful of each type of alcohol. *Salivary ethanol concentrations after 0.5 minutes were calculated as proportional to the reduction in acetaldehyde concentration after 0.5 minutes (data from [21] ). [3] , [5] . For our model, we calculated AER for the genotypes ALDH2*1/*2 and ALDH2*2/*2 as a percentage of the wild type AER (2.1 µM/sec) [58] ( Table 2 ). The symbol [A] represents acetaldehyde concentration. Table 2 . Model enzyme activities for different genotypes. The acetaldehyde elimination rate varies for different genotypes. Based on the activity levels of different genotypes compared to wild type ALDH2*1/*1 (with an AER of 2.1 µM/sec), we calculated AER for the other genotypes [3] , [5] , [58] . We created a Python program to numerically solve Equation 2 for the modeled two-step sequential enzymatic reaction with the LSODA method [59] . T he program graphs salivary acetaldehyde concentrations over time after the consumption of various alcoholic beverages for different ALDH2 genotypes ( Figure 11 ). To determine how much additional ALDH2*1 is needed for ALDH2-deficient individuals to match normal salivary acetaldehyde levels, we modified our model to account for additional ALDH2*1 (as shown in Equation 3 ). The values used for wild type ALDH2*1 were determined experimentally (data from Figure 5 ). Manipulating the concentrations of ALDH2*1 for each genotype, we determined that a supplement of 0.103 µM ALDH2*1 would allow people with homozygous mutant ALDH2*2 to match wild type ALDH2*1 activity every minute after consuming spirits ( Figure 12 ). The additional ALDH2*1 should reduce salivary acetaldehyde levels for ALDH2-deficient individuals, as well as the associated increased cancer risks. Here, concentrations of salivary acetaldehyde are shown after the consumption of spirits. A supplement of wild type ALDH2*1 changes the acetaldehyde levels in the mouth. To match homozygous wild type ALDH2*1/*1 activity, an additional 0.103 µM ALDH2*1 should be given to homozygous mutant ALDH2*2/*2 individuals. For other types of alcohol (not shown above), the same supplement of 0.103 µM ALDH2*1 also allows acetaldehyde levels in homozygous mutants to match those found in wild type individuals.
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